⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500683 | 0.82 | — | — | |
| SCHEMBL29479401 | 0.82 | — | — | |
| Phosphine SCHEMBL27727165 | 0.71 | — | — | |
| SCHEMBL29389890 | 0.71 | — | — | |
| SCHEMBL2576698 | 0.71 | — | — | |
| Methane SCHEMBL28750057 | 0.71 | — | — | |
| SCHEMBL29358262 | 0.71 | — | — | |
| SCHEMBL2266230 | 0.71 | — | — | |
| Zinc Ion SCHEMBL31038181 | 0.71 | — | — | |
| SCHEMBL23529290 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161351-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-22 | — | — | US | claimed |
| EP-4536250-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-3525781-B2 | COMPOSITION COMPRISING EPA AND DHA FOR AN ENHANCED EFFICACY OF ANTICANCER AGENTS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2023237710-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-12-14 | — | — | WO | claimed |
| CN-116786271-A | Flotation separation method for copper-molybdenum bulk concentrate | 中南大学 | 2023-09-22 | — | — | CN | claimed |
| CN-116474104-A | Small molecule targeting pharmaceutical composition for treating medulloblastoma | 南京医科大学 | 2023-07-25 | — | — | CN | claimed |
| US-11406614-B2 | Composition comprising EPA and DHA for an enhanced efficacy of anticancer agents | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2022-08-09 | — | — | US | claimed |
| US-20260043006-A1 | METHODS FOR EXPANSION OF NATURAL KILLER (NK) CELL SUBSET AND RELATED COMPOSITIONS AND METHODS | INDAPTA THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260027056-A1 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | QUETZAL THERAPEUTICS, LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12410402-B2 | Methods for expansion of natural killer (NK) cell subset and related compositions and methods | INDAPTA THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4599823-A1 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | Quetzal Therapeutics, LLC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250251410-A1 | MOLECULAR PROFILING OF TUMORS | CARIS MPI, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12364664-B2 | Lyophilized compositions comprising arsenic | QUETZAL THERAPEUTICS, LLC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-101001527-A | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2007-07-18 | — | — | CN | disclosed |
| EP-1802198-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS | Syngeta Participations AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| EP-1778013-A1 | FUNGICIDAL COMPOSITIONS | Syngeta Participations AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-07 | — | — | US | disclosed |
| WO-2006037632-A1 | SYNERGISTIC FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006015865-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PHARMACIA & UPJOHN, LLC | 2005-10-13 | — | — | US | disclosed |